PubRank

Oswaldo Castro

Author PubWeight™ 68.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004 10.51
2 Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003 8.18
3 The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010 3.78
4 Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol 2007 2.76
5 An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 2014 2.23
6 N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA 2006 2.04
7 Circumstances of death in adult sickle cell disease patients. Am J Hematol 2006 1.74
8 Hepatitis C virus in sickle cell disease. J Natl Med Assoc 2003 1.68
9 Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008 1.61
10 Severe vaso-occlusive episodes associated with use of systemic corticosteroids in patients with sickle cell disease. J Natl Med Assoc 2008 1.51
11 Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol 2005 1.47
12 HCV in sickle cell disease. J Natl Med Assoc 2003 1.39
13 Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011 1.38
14 Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003 1.29
15 Genetic screening for iron overload: No evidence of discrimination at 1 year. J Fam Pract 2007 1.27
16 Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol 2010 1.25
17 Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol 2009 1.22
18 Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the Hemochromatosis and Iron Overload Screening (HEIRS) study. Diabetes Care 2006 1.20
19 Depression in sickle cell disease. J Natl Med Assoc 2003 1.18
20 Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol 2008 1.15
21 Pulmonary hypertension of sickle cell disease beyond classification constraints. J Am Coll Cardiol 2014 1.09
22 Markers of severe vaso-occlusive painful episode frequency in children and adolescents with sickle cell anemia. J Pediatr 2011 1.05
23 Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol 2008 1.04
24 Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients. Am J Hematol 2003 1.01
25 Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises. Am J Med Sci 2003 0.99
26 Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 2006 0.99
27 Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol 2003 0.94
28 Determinants and characteristics of mean corpuscular volume and hemoglobin concentration in white HFE C282Y homozygotes in the hemochromatosis and iron overload screening study. Am J Hematol 2007 0.94
29 Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea; Hemoglobinopathy. Hematology 2000 0.90
30 Genetic determinants of haemolysis in sickle cell anaemia. Br J Haematol 2013 0.89
31 Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study. Clin Ther 2005 0.89
32 Laboratory and echocardiography markers in sickle cell patients with leg ulcers. Am J Hematol 2011 0.89
33 Hydroxyurea treatment of sickle cell anemia in hospital-based practices. Am J Hematol 2002 0.87
34 Fluorescence measurements of the labile iron pool of sickle erythrocytes. Blood 2003 0.84
35 Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol 2002 0.82
36 Accuracy of family history of hemochromatosis or iron overload: the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol 2008 0.82
37 Arterialization of peripheral venous blood in sickle cell disease. J Natl Med Assoc 2002 0.79
38 Low cobalamin levels in African Americans with and without sickle cell disease. J Natl Med Assoc 2006 0.79
39 Case 17-2005: acute chest syndrome and ARDS. N Engl J Med 2005 0.78
40 Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Transl Res 2007 0.76
41 Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia. Eur J Haematol 2014 0.75
42 Reply: Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption. Am J Respir Crit Care Med 2014 0.75
43 Physician-assisted suicide. Crit Care Med 2009 0.75
44 Pulmonary hypertension in sickle cell disease. N Engl J Med 2011 0.75
45 The celestial fire of conscience. N Engl J Med 2005 0.75
46 Central retinal vein occlusion in sickle cell disease. South Med J 2004 0.75